Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

被引：218

作者：

Kerr, K. M. ^{[1
,2
]}

Bubendorf, L. ^{[3
]}

Edelman, M. J. ^{[4
]}

Marchetti, A. ^{[5
]}

Mok, T. ^{[6
]}

Novello, S. ^{[7
]}

O'Byrne, K. ^{[8
,9
]}

Stahel, R. ^{[10
]}

Peters, S. ^{[11
]}

Felip, E. ^{[12
]}

机构：

[1] Aberdeen Royal Infirm, Dept Pathol, Aberdeen, Scotland

[2] Aberdeen Univ Med Sch, Aberdeen, Scotland

[3] Univ Basel Hosp, Inst Pathol, CH-4031 Basel, Switzerland

[4] Univ New Mexico Canc Ctr, Albuquerque, NM USA

[5] Univ Fdn, Ctr Predict Mol Med, Ctr Excellence Ageing, Chieti, Italy

[6] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China

[7] Univ Turin, Azienda Osped Univ San Luigi Orbassano, Dept Oncol, Thorac Oncol Unit, I-10124 Turin, Italy

[8] Trinity Coll Dublin, Dublin, Ireland

[9] Queensland Univ Technol, Brisbane, Qld 4001, Australia

[10] Univ Zurich Hosp, Clin Oncol, CH-8091 Zurich, Switzerland

[11] CHU Vaudois, Dept Oncol, Lausanne, Switzerland

[12] Vall dHebron Univ Hosp, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2014年 / 25卷 / 09期

关键词：

ESMO; consensus; non-small-cell lung cancer; pathology; molecular testing; recommendations; MESSENGER-RNA EXPRESSION; IN-SITU HYBRIDIZATION; EXTERNAL QUALITY ASSESSMENT; FACTOR RECEPTOR MUTATIONS; ALK GENE REARRANGEMENTS; EML4-ALK FUSION GENE; PHASE-III TRIAL; BRONCHIAL BIOPSY; INTERNATIONAL-ASSOCIATION; HISTOLOGICAL CLASSIFICATION;

D O I：

10.1093/annonc/mdu145

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The Second ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on management of patients with non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, early stage disease, locally advanced disease and advanced (metastatic) disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on recommendations for pathology and molecular biomarkers in relation to the diagnosis of lung cancer, primarily non-small-cell carcinomas.

引用

页码：1681 / 1690

页数：10

共 50 条

[31] The Emerging Role of Biomarkers in Advanced Non-Small-Cell Lung Cancer
Socinski, Mark A.
CLINICAL LUNG CANCER, 2010, 11 (03) : 149 - 159
[32] Predicting Diagnostic Gene Biomarkers for Non-Small-Cell Lung Cancer
Liang, Bin
Shao, Yang
Long, Fei
Jiang, Shu-Juan
BIOMED RESEARCH INTERNATIONAL, 2016, 2016
[33] Cancer vaccines for non-small-cell lung cancer
Palma, M.
Choudhury, A.
Mellstedt, H.
MINERVA CHIRURGICA, 2009, 64 (06) : 643 - 653
[34] Second-Line Therapy for Non-Small-Cell Lung Cancer
Arango, Belisario A.
Castrellon, Aurelio B.
Santos, Edgardo S.
Raez, Luis E.
CLINICAL LUNG CANCER, 2009, 10 (02) : 91 - 98
[35] Second-line erlotinib for non-small-cell lung cancer
Lorusso, Vito
Cinieri, Saverio
LANCET ONCOLOGY, 2012, 13 (04): : E141 - E142
[36] Australia Lung Cancer Conference 2012: focus on systemic treatment of advanced non-small-cell lung cancer
Vincent, Mark
LUNG CANCER MANAGEMENT, 2013, 2 (01) : 27 - 30
[37] Advanced Non-Small-Cell Lung Cancer
Kwon, Hyun W.
Ham, Soo-Youn
Shin, Sang W.
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20): : 1997 - +
[38] Pembrolizumab in Non-Small-Cell Lung Cancer
Sorscher, Steven
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (10): : 996 - 997
[39] Encephalitis in non-small-cell lung cancer
Costa e Silva, M.
Silva, E.
Mendes, A.
Barroso, A.
PULMONOLOGY, 2021, 27 (06): : 582 - 583
[40] Immunotherapy of non-small-cell lung cancer
Reinmuth, Niels
Merk, Martina
Duell, Thomas
ONKOLOGE, 2021, 27 (02): : 179 - 190

← 1 2 3 4 5 →